Oncosem’s €117.6M Chemotherapy Contract Fuels New Momentum in BIST 100

Oncosem is injecting fresh momentum into the BIST 100 index with a €117,583,168.80 (≈ 117.6 million TL) 24‑month chemotherapy drug preparation contract.

Strategic Partnership: 24‑Month Chemotherapy Supply Deal with Ankara Etlik City Hospital

Oncosem Oncological Systems Industry and Trade Inc. (ONCSM) has signed a contract with the Ankara Provincial Health Directorate’s Etlik City Hospital Chief Physician’s Office, deepening the company’s ties with the public sector.

Financial Impact: Contract Value’s Contribution to Balance Sheet and Profitability

■Contract value: €117.6 million

■Duration: 24 months (starting 3 August 2026)

■Expected contribution: Positive uplift to revenue and net profit

■Payment schedule: Staggered, performance‑linked installments

Market Reaction: Share Price and Volume Analysis

■Opening price: TL 28.45

■Closing price: TL 29.12 (+2.4%)

■Average daily volume: 1.8 billion shares

■Trade volume: +15% on announcement day

Risk‑Reward Assessment

■Upside: Public‑sector contract diversifies revenue and secures long‑term cash flow.

■Potential risk: Health Ministry budget cuts or regulatory changes.

■Investment recommendation: Mid‑term upward trend; suitable for investors with higher risk tolerance.

Caner Yılmaz – BIST 100 Technical and Quantitative Analysis Director: The new public‑sector contract strengthens Oncosem’s cash flow while boosting liquidity within the index. The stock remains near the 0.618 Fibonacci retracement support level, and it trades just below the Ichimoku cloud’s upper boundary, indicating a bullish bias. The 50‑day moving average is supporting price, delivering a positive momentum signal. These technical indicators suggest the share has the potential to add an additional 5‑7% gain over the next quarter.